Novamind to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Novamind to Present at H.C. Wainwright 23rd Annual Global Investment Conference
TORONTO, ON / ACCESSWIRE / September 8, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to announce its participation in the H.C. Wainwright 23rd Annual Global Investment Conference ("the Conference"), taking place virtually on September 13-15, 2021.
多伦多，于/ACCESSWIRE/2021年9月8日/诺瓦明公司(CSE：NM)(场外交易市场代码：NVMDF)(法兰克福证券交易所市场代码：HN2)(以下简称“诺瓦明”或“公司”)是一家专门从事迷幻药物的领先精神健康公司，该公司高兴地宣布参加H.C.Wainwright 23研发一年一度的全球投资大会(简称“大会”)，实际上是在2021年9月13日至15日举行的。
Novamind's CEO and Director, Yaron Conforti, will present the Company's business model focused on growing a national network of psychiatry clinics and clinical research sites to rapidly scale access to psychedelic medicine.
Novamind首席执行官兼董事亚伦·康福尔蒂将介绍该公司的商业模式，重点是发展一个全国性的精神病学诊所和临床研究网站网络，以迅速扩大迷幻药物的使用。
The corporate presentation will be available to registered Conference attendees for on-demand viewing beginning at 7:00 AM EST on September 13.
公司演示文稿将在美国东部时间9月13日上午7：00开始向已注册的与会者提供，供他们点播观看。
Qualified investors can learn more about the Conference and register to schedule a one-on-one meeting with Novamind's management here.
合格投资者可以在这里了解更多有关大会的信息，并注册安排与Novamind管理层的一对一会议。
About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.
关于诺瓦明 Novamind是一家领先的精神健康公司，通过诊所和临床研究网站的网络，使人们能够安全地获得迷幻药物。Novamind通过其Cedar精神病学诊所网络提供氯胺酮辅助的心理治疗和其他新疗法，并运营Cedar临床研究公司，这是一家专门从事迷幻药物临床试验和循证研究的合同研究组织。锡达精神病学公司和锡达临床研究公司都是Novamind公司的全资子公司。有关Novamind如何增强精神健康并指导人们完成整个康复旅程的更多信息，请访问novamind.ca。
Contact Information
Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512
联系信息诺瓦明Yaron Conforti，首席执行官兼董事电话：+1(647)953 9512
Samantha DeLenardo, VP, Communications
Email: media@novamind.ca
萨曼莎·德莱纳多(Samantha DeLenardo)，公关副总裁电子邮件：media@novamind.ca
Bill Mitoulas, Investor Relations
Email: bill@novamind.ca
比尔·米图拉斯(Bill Mitoulas)，投资者关系部电子邮件：Bill@novamind.ca
Forward-Looking Statements
前瞻性陈述
This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations including the risks detailed from time to time in the Company's public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.
本新闻稿包含前瞻性陈述。本新闻稿中除历史事实陈述外的所有陈述均为前瞻性陈述，涉及风险和不确定因素。不能保证这些陈述将被证明是准确的，实际结果和未来事件可能与这些陈述中预期的大不相同。可能导致实际结果与公司预期大不相同的重要因素，包括公司不时公开披露的详细风险。提醒读者不要过度依赖任何前瞻性信息。本新闻稿中包含的前瞻性陈述明确受本警告性声明的限制。本新闻稿中包含的前瞻性陈述是截至本新闻稿发布之日作出的，公司将根据适用法律的明确要求，公开更新或修改任何包含的前瞻性陈述。
SOURCE: Novamind Inc.
资料来源：诺瓦明公司